Difference between revisions of "Team:NCTU Formosa/Basic Part"
(34 intermediate revisions by 4 users not shown) | |||
Line 57: | Line 57: | ||
} | } | ||
.p01{ | .p01{ | ||
− | background-color:# | + | background-color: #FFD700; |
position:relative; | position:relative; | ||
height:70vh; | height:70vh; | ||
width:100%; | width:100%; | ||
left:0vw; | left:0vw; | ||
+ | opacity:0.7; | ||
} | } | ||
.p02{ | .p02{ | ||
Line 69: | Line 70: | ||
} | } | ||
.background1{ | .background1{ | ||
− | background-image:url("https://static.igem.org/mediawiki/2015/ | + | background-image:url("https://static.igem.org/mediawiki/2015/f/f2/NCTU_Formosa_E.cotector10.png"); |
background-repeat:no-repeat; | background-repeat:no-repeat; | ||
− | background-position:center; | + | background-position:center 12vh; |
position:relative; | position:relative; | ||
height:70vh; | height:70vh; | ||
width:40vw; | width:40vw; | ||
− | background-size: | + | background-size:55%; |
top:0vh; | top:0vh; | ||
left:10vw; | left:10vw; | ||
Line 86: | Line 87: | ||
position:relative; | position:relative; | ||
right:20vw; | right:20vw; | ||
− | top: | + | top:33vh; |
color:#fff; | color:#fff; | ||
z-index:100; | z-index:100; | ||
Line 162: | Line 163: | ||
text-decoration:none; | text-decoration:none; | ||
} | } | ||
− | span{font-size:18pt;} | + | .part span{font-size:18pt;} |
+ | .reference{ | ||
+ | font-size:10pt; | ||
+ | position:relative; | ||
+ | border-top:#999 1px solid; | ||
+ | } | ||
+ | #groupparts { | ||
+ | margin: 0 auto; | ||
+ | background-color:#FCFCDE;} | ||
</style> | </style> | ||
Line 174: | Line 183: | ||
<div class="content"> | <div class="content"> | ||
<h2>Basic Parts</h2> | <h2>Basic Parts</h2> | ||
− | + | ||
− | + | ||
− | + | ||
<table> | <table> | ||
<tr><td width="20%"></td><td width="13%"></td><td width="67%"></td></tr> | <tr><td width="20%"></td><td width="13%"></td><td width="67%"></td></tr> | ||
− | <tr><td class="part"><span><a href="http://parts.igem.org/Part: | + | <tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694002">BBa_K1694002</a></span><br>Lpp-OmpA-<i>Nco</i>I</td><td></td> |
<td> | <td> | ||
To display the scFv to the <i>E.coli</i> <B>outer membrane</B>, we chose Lipoprotein-Outer membrane protein A (Lpp-OmpA). | To display the scFv to the <i>E.coli</i> <B>outer membrane</B>, we chose Lipoprotein-Outer membrane protein A (Lpp-OmpA). | ||
− | According to the paper reference | + | According to the paper reference, we used the first 9 amino acids of Lpp as the signal peptide, and the 46-159 amino acids of OmpA as the anchor. All the sequences is from DH5-alpha strain itself. <br> |
The C-terminal of Lpp-OmpA, located on the outer membrane, is then be fused with the scFv part.<br> | The C-terminal of Lpp-OmpA, located on the outer membrane, is then be fused with the scFv part.<br> | ||
− | In order to change scFv part easily, we provide a basic part which contain | + | In order to change scFv part easily, we provide a basic part which contain <i>Nco</i>I restriction site. |
− | </td></tr> | + | </td></tr> |
+ | |||
+ | <tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694010">BBa_K1694010</a></span><br>Lpp-OmpA</td><td></td> | ||
+ | <td>We also provide Lpp-OmpA without <i>Nco</i>I restriction site. | ||
+ | </td></tr> | ||
<tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694003">BBa_K1694003</a></span><br> | <tr><td class="part"><span><a href="http://parts.igem.org/Part:BBa_K1694003">BBa_K1694003</a></span><br> | ||
scFv of anti-VEGF<br> | scFv of anti-VEGF<br> | ||
Line 192: | Line 203: | ||
<span><a href="http://parts.igem.org/Part:BBa_K1694005">BBa_K1694005</a></span><br> | <span><a href="http://parts.igem.org/Part:BBa_K1694005">BBa_K1694005</a></span><br> | ||
scFv of anti-HER2<br> | scFv of anti-HER2<br> | ||
− | </td><td></td><td>In our library of customized E.Cotectors, we chose two targeted drugs, <B>Avastin (Bevacizumab, anti-VEGF)<sup>[1]</sup>, Erbitux (Cetuximab, anti-EGFR)<sup>[2]</sup> from Drugbank, and a monoclonal antibody, anti-HER2<sup>[3]</sup></B>. We select the part of single chain variable fragments (scFv) , which is short and will not give too much stress for <i>E.coli</i> expressing it.</td></tr> | + | </td><td></td><td>In our library of customized E.Cotectors, we chose two targeted drugs, <B>Avastin (Bevacizumab, anti-VEGF) <sup>[1]</sup>, Erbitux (Cetuximab, anti-EGFR) <sup>[2]</sup> from Drugbank, and a monoclonal antibody, anti-HER2 <sup>[3]</sup></B>. We select the part of single chain variable fragments (scFv), which is short and will not give too much stress for <i>E.coli</i> expressing it.</td></tr> |
+ | |||
− | |||
− | |||
− | |||
Line 204: | Line 213: | ||
</td><td></td> | </td><td></td> | ||
<td>Gold binding polypeptide (GBP) is a kind of polypeptide which can bind on gold, and is usually used to immobilize proteins on gold surfaces. The mechanism of how GBP binds the gold is not clearly understood, but its polar side-chains, such as those of serine and threonine, seem to interact with gold.<br> | <td>Gold binding polypeptide (GBP) is a kind of polypeptide which can bind on gold, and is usually used to immobilize proteins on gold surfaces. The mechanism of how GBP binds the gold is not clearly understood, but its polar side-chains, such as those of serine and threonine, seem to interact with gold.<br> | ||
− | We used a 42 amino acids long GBP, which contain 3 repeated amino acid sequences [MHGKTQATSGTIQS]. To display GBP on cell surface, we used | + | We used a 42 amino acids long GBP, which contain 3 repeated amino acid sequences [MHGKTQATSGTIQS]. To display GBP on cell surface, we used long-chain fatty acid transport protein (FadL) as a transmembrane protein, selecting its first 384 amino acids to link with GBP <sup>[4]</sup>, signal peptide included. |
</td></tr> | </td></tr> | ||
</table> | </table> | ||
+ | |||
+ | <div class="content"> | ||
+ | <div class="reference"> | ||
+ | <b>Reference<br></b> | ||
+ | [1] <a href="http://www.drugbank.ca/drugs/DB00112">DrugBank: Bevacizumab (DB00112) </a><br> | ||
+ | [2] <a href="http://www.drugbank.ca/drugs/DB00002">DrugBank: Cetuximab (DB00002) </a><br> | ||
+ | [3] <a href="http://www.drugbank.ca/drugs/DB00072">DrugBank: Trastuzumab (DB00072) </a><br> | ||
+ | [4] <a href="http://www.ncbi.nlm.nih.gov/pubmed/19228193">Tae Jung Park et al. (2009) Development of a whole-cell biosensor by cell surface display of a gold-binding polypeptide on the gold surface </a><br> | ||
</div> | </div> | ||
− | |||
− | |||
</div> | </div> | ||
− | |||
− | |||
</div> | </div> | ||
+ | <div class="goto" style="background-color:#FCFCDE;"> | ||
+ | <a href="https://2015.igem.org/Team:NCTU_Formosa/Project"><img src="https://static.igem.org/mediawiki/2015/3/3c/%E7%AE%AD%E9%A0%AD1.png"; width=50vw;><br><br>Back to Navigation</a> | ||
+ | </div> | ||
+ | <div class="goto1" style="background-color:#FCFCDE;"> | ||
+ | <a href="https://2015.igem.org/Team:NCTU_Formosa/Composite_Part"><img src="https://static.igem.org/mediawiki/2015/c/c2/%E7%AE%AD%E9%A0%AD2.png"; width=50vw;><br><br>Go to Composite parts</a> | ||
</div> | </div> | ||
</body> | </body> | ||
</html> | </html> | ||
+ | |||
{{Team:NCTU_Formosa/footer}} | {{Team:NCTU_Formosa/footer}} |
Latest revision as of 03:53, 19 September 2015
Basic Parts
Basic Parts
BBa_K1694002 Lpp-OmpA-NcoI |
To display the scFv to the E.coli outer membrane, we chose Lipoprotein-Outer membrane protein A (Lpp-OmpA).
According to the paper reference, we used the first 9 amino acids of Lpp as the signal peptide, and the 46-159 amino acids of OmpA as the anchor. All the sequences is from DH5-alpha strain itself. The C-terminal of Lpp-OmpA, located on the outer membrane, is then be fused with the scFv part. In order to change scFv part easily, we provide a basic part which contain NcoI restriction site. | |
BBa_K1694010 Lpp-OmpA | We also provide Lpp-OmpA without NcoI restriction site. | |
BBa_K1694003 scFv of anti-VEGF BBa_K1694004 scFv of anti-EGFR BBa_K1694005 scFv of anti-HER2 | In our library of customized E.Cotectors, we chose two targeted drugs, Avastin (Bevacizumab, anti-VEGF) [1], Erbitux (Cetuximab, anti-EGFR) [2] from Drugbank, and a monoclonal antibody, anti-HER2 [3]. We select the part of single chain variable fragments (scFv), which is short and will not give too much stress for E.coli expressing it. | |
BBa_K1694006 GBP BBa_K1694007 FadL-GBP | Gold binding polypeptide (GBP) is a kind of polypeptide which can bind on gold, and is usually used to immobilize proteins on gold surfaces. The mechanism of how GBP binds the gold is not clearly understood, but its polar side-chains, such as those of serine and threonine, seem to interact with gold. We used a 42 amino acids long GBP, which contain 3 repeated amino acid sequences [MHGKTQATSGTIQS]. To display GBP on cell surface, we used long-chain fatty acid transport protein (FadL) as a transmembrane protein, selecting its first 384 amino acids to link with GBP [4], signal peptide included. |